Edaravone Utilization and Outcomes within a Nationally Integrated Health System
Kathryn Tortorice1, Michelle Vu1, Xiang Ming Wei1, Diane Dong1, Kwan Hur1, Jennifer Zacher1, Francesca Cunningham1, Peter Glassman1, Chester Good1
1US Department of Veterans Affairs
Objective:
This is a pharmacovigilance surveillance initiative to evaluate the patient characteristics, utilization, safety and effectiveness of edaravone use.
Background:
The Department of Veterans Affairs (VA) provides care for over 4,000 Veteran patients with amyotrophic lateral sclerosis (ALS).Given limited real-world data, the VA initiated a surveillance effort to monitor the safe and appropriate use of edaravone.

Design/Methods:
Retrospective, matched cohort (edaravone vs. riluzole) analysis. Veteran patients with a diagnosis of ALS with a prescription of edaravone or riluzole between 8/1/2017 to 12/31/2018.

Results:

Mortality (acutely and among chronic users) was similar between cohorts. Both acute and long-term discontinuation events were more common within the riluzole cohort compared to within the edaravone cohort. More acute all-cause hospitalization events, with shorter time to hospitalization, occurred in the edaravone cohort compared to the riluzole cohort.

 

 

Conclusions:

Preliminary trends show increased risk of acute and long term ALS associated hospitalization and PEG placement with edaravone compared to riluzole.

Discontinuation, both acute and long-term were greater with riluzole compared to edaravone, potentially related to greater ALS progression with riluzole.